Qube Research & Technologies (QRT)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$20.2M	Buy	1,345,150 +462,931	+52%	+$11.1M	0.02%	995
2026 Q2	$29.5M	Sell	882,219 -32,541	-4%	-$808K	0.03%	721
2026 Q1	$19.2M	Buy	+914,760	New	+$20.6M	0.02%	903
2024 Q2	–	Sell	-642	Closed	-$30K	–	4554
2024 Q1	$30K	Buy	+642	New	+$30.3K	﹤0.01%	3615
2022 Q4	–	Sell	-30,774	Closed	-$1.27M	–	2897
2022 Q3	$1.27M	Buy	+30,774	New	+$1.58M	0.01%	1105
2021 Q3	–	Sell	-30,246	Closed	-$2.88M	–	2677
2021 Q2	$2.88M	Buy	30,246 +25,550	+544%	+$2.66M	0.03%	581
2021 Q1	$535K	Sell	4,696 -11,876	-72%	-$1.62M	0.01%	1139
2020 Q4	$2.29M	Buy	+16,572	New	+$1.97M	0.03%	566

Other funds holding RARE

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

Qube Research & Technologies (QRT)'s RARE Position: Q3 2026 in Review

Qube Research & Technologies (QRT) increased its Ultragenyx Pharmaceutical (RARE) stake by 52% in Q3 2026, buying an estimated $11.1M and bringing the position to 1,345,150 shares worth $20.2M. The position accounts for 0.02% of the portfolio, ranked #995.

Qube Research & Technologies (QRT) first reported a position in RARE in Q4 2020 and has held it in 8 quarters since. The position peaked at $29.5M in Q2 2026. 163 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

Qube Research & Technologies (QRT) held 1,345,150 shares of Ultragenyx Pharmaceutical worth $20.2M as of Q3 2026.
Qube Research & Technologies (QRT) bought 462,931 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $11.1M.
Ultragenyx Pharmaceutical made up 0.02% of Qube Research & Technologies (QRT)'s portfolio in Q3 2026, its #995 holding.
Qube Research & Technologies (QRT) first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and has held it in 8 quarters since.
Qube Research & Technologies (QRT)'s Ultragenyx Pharmaceutical position peaked at $29.5M in Q2 2026.
163 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.